VIMIZIM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIMIZIM (VIMIZIM).
VIMIZIM (elosulfase alfa) is a recombinant human N-acetylgalactosamine-6-sulfatase that hydrolyzes the sulfate ester bond at position 6 of N-acetylgalactosamine in chondroitin sulfate and keratan sulfate, thereby reducing glycosaminoglycan (GAG) accumulation in patients with Morquio A syndrome (mucopolysaccharidosis IVA).
| Metabolism | Elosulfase alfa is a recombinant protein; it is expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathway or enzyme involvement has been characterized. |
| Excretion | Primarily renal. No specific data on biliary or fecal elimination; as a recombinant enzyme, likely catabolized to peptides and amino acids, with renal excretion of metabolites. |
| Half-life | Terminal elimination half-life approximately 9.8 days (range 7.7–13.8 days) in patients with mucopolysaccharidosis VI (MPS VI). Long half-life supports weekly intravenous dosing. |
| Protein binding | Not extensively bound; specific binding proteins not characterized. As a recombinant human enzyme, expected to have low non-specific protein binding. |
| Volume of Distribution | Mean volume of distribution at steady state approximately 283 mL/kg (range 215–412 mL/kg), suggesting limited tissue distribution mainly to plasma and extracellular fluid. |
| Bioavailability | Not applicable for oral route (enzyme degraded in GI tract). Administered intravenously; bioavailability is 100%. |
| Onset of Action | Urinary glycosaminoglycan (GAG) reduction observed within 2 weeks of initiating weekly IV infusions; clinical improvement in endurance and growth may take several months. |
| Duration of Action | Duration of effect on urinary GAG levels persists for approximately 2–3 weeks after last dose; sustained clinical benefit requires continued weekly administration. |
2 mg/kg administered intravenously once weekly over approximately 4 hours. Pretreat with antihistamines and antipyretics 30-60 minutes prior to infusion.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; clinical studies did not include patients with severe renal impairment, so caution is advised. GFR-based modifications not established. |
| Liver impairment | No specific dose adjustment required for hepatic impairment; Child-Pugh based modifications not established due to lack of data in this population. |
| Pediatric use | Same as adult dosing: 2 mg/kg intravenously once weekly. Safety and efficacy established in pediatric patients aged 16 weeks and older. Weight-based dosing recommended. |
| Geriatric use | No specific dose adjustment recommended; clinical studies included limited elderly patients (age 65 and older), no overall differences in safety or efficacy observed. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VIMIZIM (VIMIZIM).
| Breastfeeding | It is unknown if elosulfase alfa is excreted in human breast milk. No M/P ratio is available. Given its large molecular weight (~100 kDa), systemic absorption by the infant is unlikely. Caution advised; consider the developmental and health benefits of breastfeeding alongside the mother's clinical need. |
| Teratogenic Risk | VIMIZIM (elosulfase alfa) is an enzyme replacement therapy for mucopolysaccharidosis type IVA. No adequate human data exist in pregnancy. In animal studies, no teratogenic effects were observed at doses up to 3 times the human dose. However, due to potential disruptions in glycosaminoglycan metabolism, theoretical risks exist. Advised use only if benefit outweighs risk. Trimester-specific risks: first trimester unknown; second and third trimesters no reported fetal harm. |
■ FDA Black Box Warning
WARNING: ANAPHYLAXIS AND SEVERE HYPERSENSITIVITY REACTIONS. Anaphylaxis and severe hypersensitivity reactions, including life-threatening anaphylaxis, have occurred in patients treated with VIMIZIM. Some reactions were severe and may require emergency medical treatment. Closely observe patients during and after infusion. Ensure that appropriate medical support is readily available.
| Serious Effects |
["History of life-threatening hypersensitivity reaction to elosulfase alfa or any of its excipients."]
| Precautions | ["Anaphylaxis and severe hypersensitivity reactions: Observe patients during and for an appropriate period after infusion; have emergency medical support available.","Acute infusion reactions: Reactions may include urticaria, bronchospasm, and hypotension; manage with slowing or stopping infusion and administering antihistamines, corticosteroids, or epinephrine as needed.","Risk of acute respiratory compromise: Patients with compromised respiratory function may be at risk of serious exacerbation due to infusion reactions.","Spinal cord compression: Monitor for signs and symptoms of spinal cord compression, which is a known complication of Morquio A syndrome and may require surgical intervention."] |
Loading safety data…
| Fetal Monitoring | Standard prenatal care is recommended. No specific fetal monitoring is mandated. Clinical monitoring for infusion-related reactions and hypersensitivity during administration in pregnancy. Consider periodic fetal growth assessment via ultrasound due to potential placental glycosaminoglycan accumulation (theoretical). |
| Fertility Effects | No studies have assessed the effects of elosulfase alfa on human fertility. Animal studies showed no adverse effects on mating indices or fertility. Theoretical concerns due to underlying disease (MPS IVA) and chronic illness may affect fertility; no direct drug-related impact. |